石药集团(01093)：普卢格列汀达格列净二甲双胍缓释片在中国获临床试验批准

Core Viewpoint - The approval of the combination drug consisting of Ploglitazone, Dapagliflozin, and Metformin by the National Medical Products Administration of China marks a significant advancement in diabetes treatment, providing a new therapeutic option for type 2 diabetes patients [1][2] Group 1: Product Approval and Composition - The product is the first globally approved clinical combination formulation of Ploglitazone, Dapagliflozin, and Metformin [1] - Ploglitazone is a DPP-4 inhibitor that enhances insulin secretion and improves blood glucose control [1] - Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion by reducing glucose reabsorption [1] - Metformin is a biguanide that improves glucose tolerance and lowers both fasting and postprandial blood glucose levels [1] Group 2: Clinical Application and Benefits - The approved clinical indication is for use in adults with type 2 diabetes who have inadequate blood glucose control with Metformin alone, in conjunction with diet and exercise [2] - The combination drug's complementary mechanisms address multiple pathophysiological aspects of diabetes, effectively controlling blood sugar levels [2] - The formulation simplifies the treatment regimen, reduces the number of medications needed, and enhances patient adherence to therapy, indicating high clinical development value [2] - This product will provide new treatment options for type 2 diabetes patients and expand the company's product line in the metabolic disease sector [2]